Head to Head Survey: Shuttle Pharmaceuticals (NASDAQ:SHPH) & Medicure (OTCMKTS:MCUJF)

Shuttle Pharmaceuticals (NASDAQ:SHPH) and Medicure (OTCMKTS:MCUJF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, dividends, analyst recommendations and risk.

Profitability

This table compares Shuttle Pharmaceuticals and Medicure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%
Medicure	-21.65%	-44.34%	-26.22%

Earnings and Valuation

This table compares Shuttle Pharmaceuticals and Medicure”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shuttle Pharmaceuticals	N/A	N/A	-$11.72 million	($4.77)	-0.86
Medicure	$20.65 million	0.41	-$5.08 million	($0.47)	-1.74

Medicure has higher revenue and earnings than Shuttle Pharmaceuticals. Medicure is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are held by company insiders. Comparatively, 12.9% of Medicure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Shuttle Pharmaceuticals has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500. Comparatively, Medicure has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Shuttle Pharmaceuticals and Medicure, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shuttle Pharmaceuticals	1	0	0	0	1.00
Medicure	0	0	0	0	0.00

Summary

Medicure beats Shuttle Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.

About Medicure

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.